Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"
Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"
复制标题
DOI：
10.1093/cid/civ197
复制
发表时间：
2015-06-15
影响因子：
11.8
通讯作者：
Feld, Jordan J.
中科院分区：
文献类型：
--
作者：
Dore, Gregory J.;Feld, Jordan J.
未来十年将是公共卫生应对丙型肝炎病毒（HCV）感染的关键时期。HCV感染的直接作用抗病毒（DAA）治疗的快速发展给HCV领域带来了相当大的乐观，现实的希望是，治疗干预将很快提供接近最佳的疗效，耐受性良好的短期，全口服方案。随着丙型肝炎治疗发展的顶峰接近，广泛实施无干扰素DAA方案仍存在几个关键障碍。HCV筛查和疾病评估的程度、全球和国家公共卫生优先级以及药物定价将决定引入这些令人兴奋的新HCV疗法对疾病负担的潜在影响。公共卫生伙伴关系和宣传将是至关重要的，以消除障碍，提高丙型肝炎病毒治疗的机会。
The next decade will be a crucial period in the public health response to hepatitis C virus (HCV) infection. The rapid development of direct-acting antiviral (DAA) therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon provide near-optimal efficacy with well-tolerated short-duration, all-oral regimens. As the zenith in HCV therapeutic development approaches, there remain several key obstacles to the broad implementation of interferon-free DAA regimens. The extent of HCV screening and disease assessment, global and national public health prioritization, and drug pricing will determine the potential impact on disease burden derived from introduction of these exciting new HCV therapies. Public health partnerships and advocacy will be crucial to remove barriers to enhanced HCV treatment access.